Moderna, Inc. (NASDAQ:MRNA) Shares Bought by Empirical Finance LLC

Empirical Finance LLC grew its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 4.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,613 shares of the company’s stock after acquiring an additional 334 shares during the period. Empirical Finance LLC’s holdings in Moderna were worth $576,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of MRNA. Ashton Thomas Private Wealth LLC purchased a new position in Moderna in the 2nd quarter valued at approximately $26,000. Family Firm Inc. purchased a new position in shares of Moderna in the second quarter valued at $33,000. Bank & Trust Co acquired a new position in shares of Moderna during the 2nd quarter worth $36,000. Hanseatic Management Services Inc. purchased a new stake in shares of Moderna in the 2nd quarter worth about $48,000. Finally, Plato Investment Management Ltd grew its stake in Moderna by 230.4% in the 2nd quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock valued at $49,000 after acquiring an additional 288 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Stock Down 7.3 %

Shares of MRNA opened at $36.85 on Monday. The firm has a market cap of $14.18 billion, a PE ratio of -6.33 and a beta of 1.69. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The company’s fifty day moving average is $58.56 and its two-hundred day moving average is $96.78. Moderna, Inc. has a fifty-two week low of $35.80 and a fifty-two week high of $170.47.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. The firm had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The firm’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.39) earnings per share. Analysts forecast that Moderna, Inc. will post -9.43 earnings per share for the current year.

Insider Transactions at Moderna

In related news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the transaction, the chief financial officer now owns 8,600 shares in the company, valued at approximately $682,754. The trade was a 13.32 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last quarter, insiders sold 2,930 shares of company stock worth $217,170. 15.70% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

MRNA has been the subject of a number of research reports. HSBC upgraded shares of Moderna from a “reduce” rating to a “hold” rating and set a $82.00 target price for the company in a research report on Wednesday, August 28th. The Goldman Sachs Group reduced their target price on Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a research note on Monday, September 16th. Sanford C. Bernstein assumed coverage on Moderna in a report on Thursday, October 17th. They set a “market perform” rating and a $55.00 target price on the stock. JPMorgan Chase & Co. cut their price target on Moderna from $70.00 to $59.00 and set an “underweight” rating for the company in a report on Monday, November 4th. Finally, Deutsche Bank Aktiengesellschaft raised Moderna from a “sell” rating to a “hold” rating and decreased their price objective for the company from $85.00 to $80.00 in a research note on Wednesday, August 7th. Three equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $90.22.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.